Biomarker testing, referrals, screening, treatment access, and clinical trial barriers were examined during this recent IVBM.
|Podcasts|September 17, 2019
Exploring Reference-Based Pricing as a Method for Lowering Healthcare Costs
Reference-based pricing has been touted as a way to contain healthcare costs while ensuring quality of care. We talk with with David Henka, chief executive officer of ActiveRADAR, to dig deeper into how the method is used in practice and what program results have shown.
Advertisement
Reference-based pricing has been touted as a way to contain healthcare costs while ensuring quality of care. When implemented, health plans or employers compare the costs of all brand-name and generic drig options within a certain therapeutic category and identify the lowest cost options. From there, copays are adjusted to encourage the use of the lowest cost alternatives, with plans covering the cost of a drug or service up until the reference point.
With research showing that these programs can reduce costs by an average 20% each year, we sat down with David Henka, chief executive officer of ActiveRADAR, to dig deeper into how the method is used in practice and what program results have shown.
Listen above or through one of these podcast services:
Advertisement
Related to this article
Oncologists say advances in testing and treatment are outpacing staffing, pay, and access.
Home NB-UVB phototherapy matches office results, boosts psoriasis treatment adherence, and may improve access, but long-term safety, equity, and oversight lag.
Upper-extremity synovial sarcoma required more staged surgery, while lower-extremity disease carried more complications and metastases.
In the US alone, 1.1 million individuals are living with the progressive neurodegenerative movement disorder, and 90,000 are diagnosed each year.
Baricitinib is now FDA approved for adolescents 12 and older with severe alopecia areata, extending the once-daily pill beyond adults.
A new type of eye drug matched standard anti-VEGF therapy in a large trial for diabetic macular edema, a disease affecting 1.6 million Americans.
At a Stakeholder Interchange convened by The American Journal of Managed Care® in Tampa, Florida, an academic-community mix of hematologist-oncologists and pharmacists debated prior authorization, site-of-care payment disparities, and how aggressively to push bispecific antibody regimens to community practices treating patients with relapsed/refractory multiple myeloma.
Advertisement
Advertisement
Trending on AJMC
1
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
2
Tavapadon for Parkinson Disease Approved by FDA
3
Health System Pharmacies Keep Patients on GLP-1 Therapy
4
NCCN Journal Publishes Guidelines Update in Mantle Cell Lymphoma
5